Form 497 DEUTSCHE DWS STATE TAX-F
Tweet
Share
E-mailSUPPLEMENT TO THE CURRENTLY EFFECTIVE PROSPECTUSES
DWS New York Tax-Free Income Fund
The following information is added to the disclosure relating to the fund under the “Management Fee” sub-heading of the “WHO MANAGES AND OVERSEES THE FUND” section of the fund’s prospectuses:
Effective October 1, 2021, DWS New York Tax-Free Income Fund pays the Advisor a fee, calculated daily and paid monthly, at the annual rate of 0.400% on the first $250 million of the fund’s average daily net assets, 0.370% on the next $750 million
of the fund’s average daily net assets, 0.350% on the next $1.5 billion of the fund’s average daily net assets, 0.330% on
the next $2.5 billion of the fund’s average daily net assets, 0.300% on the next $2.5 billion of the fund’s average daily
net assets, 0.280% on the next $2.5 billion of the fund’s average daily net assets, 0.260% on the next $2.5 billion of the fund’s
average daily net assets, and 0.250% of the fund’s average daily net assets thereafter. Prior to October 1, 2021, the fund
paid the Advisor a fee, calculated daily and paid monthly, at the annual rate of 0.450% on the first $250 million of the fund’s
average daily net assets, 0.420% on the next $750 million of the fund’s average daily net assets, 0.400% on the next $1.5 billion of the fund’s average daily net assets, 0.380% on the next $2.5 billion of the fund’s average daily net assets,
0.350% on the next $2.5 billion of the fund’s average daily net assets, 0.330% on the next $2.5 billion of the fund’s average
daily net assets, 0.310% on the next $2.5 billion of the fund’s average daily net assets, and 0.300% of the fund’s average
daily net assets thereafter.
Please Retain This Supplement for Future Reference
September 27, 2021
PROSTKR21-58
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- The Missing Piece - TUC s.r.l presents TUC.tiny: the key to access New Mobility
- Enlight Research analysed INVL Technology’s financial results for 2023
- Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
